

How Brazil use MDSAP?

Thiago Rezende Pereira Cunha ANVISA - BRAZIL











Medical Devices Regulatory Scheme







(MDSAP)



- Final Product
- Final Release + 1 Production stage
- SaMD

 Compulsory for registration of devices Risk Class III and IV





- MDSAP
- Confidential Information / RAs Agreement
- Audit Report by IMDRF Country / Risk analysis
- Anvisa GMP Inspection





- Reports analyzed by Anvisa Specialist;
- Reports must cover RDC n°16/2013 requirements;
- No NCs grades 4 or 5 issued;
- NCs grades 1 to 3 with satisfactory action plans.





5-day notice

 Anvisa may also investigate information reported on <u>5-day notice</u> related with possible risks to patients or public health.





 NCs raised against other RAs requirements will not impact the Certification or be investigated.



GMP Certificate



- If the company complies with the GMP, the GMP certificate is issued.
- It is published in the Government Official Journal <u>www.in.gov.br</u>
- It is valid for 2 years since its publication.
- Can be cancelled in case of marketing deviations or other significant events.

Use of MDSAP Reports by ANVISA



- 38 Certificates Issued in 2017 (4.7%)
- 107 Certificates Issued in 2018 (19,3%)
- 321 Certificates Issued in 2019 (48,7%)



ANVISA On-Site International Inspections:



- 238 Inspection (2017)
- 110 Inspections (2018)
- 84 Inspections (2019)





Thank you!

Brazilian Health Regulatory Agency Agência Nacional de Vigilância Sanitária - Anvisa

mdsap@anvisa.gov.br

www.anvisa.gov.br

